Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2007 Sep;68(5):349–359. doi: 10.1016/j.curtheres.2007.11.001

Effectiveness and Tolerability of Istradefylline for the Treatment of Restless Legs Syndrome: An Exploratory Study in Five Female Patients

John DeCerce 1,a, Lisa F Smith 1, Walter Gonzalez 1, Neil M Sussman 2
PMCID: PMC3969964  PMID: 24692766

Abstract

Background: Studies of istradefylline (KW6002), an adenosine A2A-receptor antagonist, have provided evidence of its efficacy as a nondopaminergic antiparkinsonian drug. Antiparkinsonian drugs have also had efficacy in treating restless legs syndrome (RLS).

Objectives: The aims of this study were to assess the effectiveness and tolerability of istradefylline in the treatment of RLS.

Methods: This was a single-center, multiparametric, prospective trial of istradefylline as a treatment for moderate to severe idiopathic RLS. It was conducted at the Shands/Jacksonville Sleep Disorders Center, University of Florida, Jacksonville, Florida, from March 2003 to October 2003. Patients received a single PO 80-mg dose QD of istradefylline in the late afternoon or early evening for 6 weeks. Appropriate tolerability evaluations (ie, vital assessments, physical examination, clinical laboratory tests, and electrocardiogram) were performed at screening, while on study drug, and after withdrawal of study drug.

Results: Fifteen participants (mean [SD] age, 61 [7.1] years; range, 50-69 years) were screened for enrollment. The mean duration of RLS was 18 years. Of the 15 potential patients, 6 did not meet entry criteria, 2 withdrew consent, 1 had not completed baseline procedures at the time of study suspension, and 1 was excluded for administrative reasons. Therefore, a total of 5 patients received the study drug. Of these, 3 (60%) patients responded favorably to istradefylline treatment. Improvement in the periodic limb movement index was observed in 3 patients compared with baseline (patients 2, 4, and 5 [index score: 6, 4, 9 vs 50, 35, 18, respectively]). Improvement in the International RLS Rating Scale scores was observed in 3 patients compared with baseline (patients 2, 4, and 5 [index score: 7, 23, 9 vs 35, 25, 20, respectively]). There was a return to baseline severity in 2 of the 3 patients after withdrawal of study drug. Improvement in RLS symptoms was observed in 3 patients treated with istradefylline for 6 weeks. A clinical worsening of baseline insomnia was observed in 2 patients.

Conclusions: Although we could not definitively conclude a beneficial effect based on this small exploratory trial, we found the data to be encouraging. The study drug was well tolerated. Further study of this compound in the treatment of RLS is justified.

Key words: restless legs syndrome, periodic limb movements, polysomnography, istradefylline, adenosine antagonists, dopaminergic agonist, KW6002

Full Text

The Full Text of this article is available as a PDF (597.5 KB).

Footnotes

This study was presented in part as a poster at the Associated Professional Sleep Societies, LLC, June 17-22, 2006, Salt Lake City, Utah (Abstract 0802).

References

  • 1.Hening W, Allen R, Earley C. The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep. 1999;22:970–999. [PubMed] [Google Scholar]
  • 2.Vignatelli L, Billiard M, Clarenbach P, for the EFNS Task Force EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol. 2006;13:1049–1065. doi: 10.1111/j.1468-1331.2006.01410.x. [DOI] [PubMed] [Google Scholar]
  • 3.Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS) Sleep Med. 2004;5:9–14. doi: 10.1016/j.sleep.2003.07.005. [DOI] [PubMed] [Google Scholar]
  • 4.Bara-Jimenez W, Sherzai A, Dimitrova T. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology. 2003;61:293–296. doi: 10.1212/01.wnl.0000073136.00548.d4. [DOI] [PubMed] [Google Scholar]
  • 5.Weiss SM, Benwell K, Cliffe IA. Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease. Neurology. 2003;61(Suppl 6):S101–S106. doi: 10.1212/01.wnl.0000095581.20961.7d. [DOI] [PubMed] [Google Scholar]
  • 6.Ochi M, Shiozaki S, Kase H. Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease. Neuroscience. 2004;127:223–231. doi: 10.1016/j.neuroscience.2004.04.050. [DOI] [PubMed] [Google Scholar]
  • 7.Bibbiani F, Oh JD, Petzer JP. A2A antagonist prevents dopamine agonistinduced motor complications in animal models of Parkinson's disease. Exp Neurol. 2003;184:285–294. doi: 10.1016/s0014-4886(03)00250-4. [DOI] [PubMed] [Google Scholar]
  • 8.Hauser RA, Hubble JP, Truong DD, for the Istradefylline US-001 Study Group Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology. 2003;61:297–303. doi: 10.1212/01.wnl.0000081227.84197.0b. [DOI] [PubMed] [Google Scholar]
  • 9.Kanda T, Jackson MJ, Smith LA. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol. 2000;162:321–327. doi: 10.1006/exnr.2000.7350. [DOI] [PubMed] [Google Scholar]
  • 10.Kase H, Aoyama S, Ichimura M, for the KW-6002 US-001 Study Group Progress in pursuit of therapeutic A2A antagonists: The adenosine A2A receptor selective antagonist KW6002: Research and development toward a novel nondopaminergic therapy for Parkinson's disease. Neurology. 2003;61(Suppl 6):S97–S100. doi: 10.1212/01.wnl.0000095219.22086.31. [DOI] [PubMed] [Google Scholar]
  • 11.Data on file. Kyowa Pharmaceuticals; Princeton, New Jersey: 2005. [Google Scholar]
  • 12.World Medical Association (WMA) Declaration of Helsinki. 4th (Somerset West) Amendment. WMA; Ferney-Voltaire, France: 1996. [Google Scholar]
  • 13.European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation-World Health Organization . Guideline for Good Clinical Practice. EMEA; London, UK: 1997. [Google Scholar]
  • 14.Allen RP, Pichietti D, Hening WA, for the Restless Legs Syndrome Diagnosis and Epidemiology Workshop at the National Institutes of Health and the International Restless Legs Syndrome Study Group Restless legs syndrome: Diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101–119. doi: 10.1016/s1389-9457(03)00010-8. [DOI] [PubMed] [Google Scholar]
  • 15.Allen RP, Kushida CA, Atkinson MJ, for the RLS QoL Consortium Factor analysis of the International Restless Legs Syndrome Study Group's scale for restless legs severity. Sleep Med. 2003;4:133–135. doi: 10.1016/s1389-9457(02)00193-4. [DOI] [PubMed] [Google Scholar]
  • 16.The Atlas Task Force Recording and scoring leg movements. Sleep. 1993;16:748–759. [PubMed] [Google Scholar]
  • 17.Iber C, Ancoli-Israel S, Chesson A, Quan SF, for the American Academy of Sleep Medicine . The American Academy of Sleep Medicine Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications. 1st ed. American Academy of Sleep Medicine; Westchester, III: 2007. [Google Scholar]
  • 18.Scoring rules and examples: A preliminary report from the Sleep Disorders Atlas Task Force of American Sleep Disorders Association EEG arousals. Sleep. 1992;15:173–184. [PubMed] [Google Scholar]
  • 19.Sun ER, Chen CA, Ho G. Iron and the restless legs syndrome. Sleep. 1998;21:371–377. [PubMed] [Google Scholar]
  • 20.Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, Md: National Institute of Mental Health. 1976. pp. 217–222. DHEW Publication No. 76-338. [Google Scholar]
  • 21.Rechtschaffen A, Kales A. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Public Health Service, US Government Printing Office; Washington, DC: 1968. [Google Scholar]
  • 22.Huang ZL, Qu WM, Eguchi N. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci. 2005;8:858–859. doi: 10.1038/nn1491. [DOI] [PubMed] [Google Scholar]
  • 23.Haba-Rubio J, Staner L, Cornette F. Acute low single dose of apomorphine reduces periodic limb movements but has no significant effect on sleep arousals: A preliminary report. Neurophysiol Clin. 2003;33:180–184. doi: 10.1016/s0987-7053(03)00056-x. [DOI] [PubMed] [Google Scholar]
  • 24.Saletu M, Anderer P, Saletu B. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables. Neuropsychobiology. 2000;41:190–199. doi: 10.1159/000026659. [DOI] [PubMed] [Google Scholar]
  • 25.Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: A double-blind randomized trial. Neurology. 1999;52:938–943. doi: 10.1212/wnl.52.5.938. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES